News AbbVie charts a new course for CGRPs in menstrual migraine AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.
News UK review recommends 'L plates' for new healthcare AIs A report has concluded that the current regulatory framework in the UK is inadequate for healthcare AI, and makes 44 recommendations to set it right.
News Encoded raises $275m for Dravet therapy and other financings Our round-up of biotech financings is headed by Encoded, which has raised $275m to advance its gene therapy for Dravet syndrome into pivotal trials.
News Five indications added to Pharmacy First prescribing scheme Some pharmacists in England can now prescribe drugs for acne, migraines, scabies, ear infections, and rhinitis under the Pharmacy First scheme.
News Could UK clinical trial revamp unlock closer ties with Canad... Two senior figures in Canada's life science sector have said they see scope for greater collaboration with the UK following clinical trial reforms.
News Reviews underway of first drug for rare disease MOGAD Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.